Produced in collaboration with CLL Society and The Leukemia & Lymphoma Society.
Support for this patient education program was provided by AstraZeneca; Pharmacyclics LLC, an AbbVie Company; and Janssen Biotech, Inc.
A diagnosis of chronic lymphocytic leukemia (CLL) can be a challenging experience for patients, families, and caregivers. Learning about the condition and the available treatment, resource, and support options can help patients successfully navigate the disease.
Dr. Matthew Davids, Associate Professor of Medicine at Harvard Medical School and Associate Director, Center for Chronic Lymphocytic Leukemia, at the Dana-Farber Cancer Institute., along with an expert panel explores the latest findings on long-term efficacy, side-effect management, and adopting healthy lifestyles to improve outcomes. A CLL patient being treated with a BTK inhibitor will share their perspective.
This educational module is the first in a series specifically designed to help patients and caregivers understand the available treatment options for CLL across the continuum of care, learn about the details of BTK-inhibitor treatments, and confidently talk with their doctors and other clinicians to align their goals and priorities for care.
- Challenges managing treatment with BTK inhibitors
- Newly diagnosed and relapsed/refractory settings
- Long-term efficacy of BTK inhibitors
- Adverse-event management
- Healthy lifestyles to improve outcomes
Come back in September for “Aligning Patient and Provider Goals,” as expert clinicians answer patient/caregiver-submitted questions about CLL.
Matthew S. Davids, MD, MMSC
Associate Professor of Medicine, Harvard Medical School
Matthew S. Davids, MD, MMSC, is an attending physician in the Lymphoma Program of the Division of Hematologic Malignancies and associate director of the CLL Center at Dana-Farber Cancer Institute, as well as an associate professor of medicine at Harvard Medical School in Boston. He has an active translational research program in chronic lymphocytic leukemia (CLL), studying Bcl-2 biology in his laboratory and leading clinical trials to evaluate a variety of novel therapeutic strategies in patients with CLL and other hematologic malignancies. Dr Davids received his medical degree from Yale School of Medicine in New Haven, Connecticut.
Susan O'Brien, MD
Professor, Division of Hematology/Oncology, University of California, Irvine School of Medicine Associate Director for Clinical Sciences Chao Family Comprehensive Cancer Center